Mutational spectrum
Mainly frameshift, nonsense, splice site and missense mutations. Less frequently large deletions (one or more exons) and rarely balanced inversions and translocations. Mutations are heterozygous, and mosaic mutations have been described. At present, more than 100 pathogenic mutations are known for the two genes together, but mutations in EP300 are much less common (only 11 so far). [2] [3] [4] [5] [6] [7] [8] [9] Mutations may remove the 5¢ or the 3¢end of CREBBP and adjacent genomic segments, which causes the 16p13.3 contiguous gene deletion syndrome. [10] [11] [12] For both genes a mutation database is available that also includes unpublished mutations:
CREBBP: http://chromium.liacs.nl/LOVD2/home.php?select_db¼ CREBBP EP300: http://chromium.liacs.nl/LOVD2/home.php?select_db¼EP300
Analytical methods
Genomic sequencing of the coding regions, MLPA and quantitative multiplex fluorescent-PCR for all coding exons for the detection of large deletions and duplications. Microarray-based chromosome analysis or fluorescence in situ hybridization for the sizing of large deletions removing the first or last coding exon. 11, 12 Conventional cytogenetics is usually normal except for rare cases resulting from balanced translocations.
Analytical validation
Direct sequencing of both DNA strands; verification of sequence and MLPA results on a second DNA extraction or second PCR or hybridization (MLPA). Index case in case that family had not been tested: Not relevant, RSTS is a congenital disorder. In addition, almost all patients occur from de novo mutations, therefore, the recurrence risk is low (o1%). 13 3. CLINICAL UTILITY 3.1.1 Can a diagnosis be made other than through a genetic test? 3.1.2 Describe the burden of alternative diagnostic methods to the patient The burden of clinical assessment is usually low. However, a clinical diagnosis cannot be made in all cases, but only in typical cases, and can be difficult at a very young age. The burden for the family of uncertainty about the diagnosis for a prolonged period of time is high.
How is the cost effectiveness of alternative diagnostic methods to be judged?
In patients with the typical phenotype the cost effectiveness is high, but it decreases significantly with increasing uncertainty of the diagnosis. An early genetically proven diagnosis may avoid later alternative and expensive diagnostics and/or management strategies. Lack of a molecularly confirmed diagnosis also means that parents do not have the option for prenatal studies in future pregnancies.
Will disease management be influenced by the result of a genetic test?
Therapy: Depends on clinical manifestations: tube feeding, speech therapy, cardiac surgery, correction of glaucoma, orthopedic surgery for thumbs, hips and spine and antibiotic prophylaxis for airway infections.
Prognosis: Good for life expectancy, moderate for developmental abilities. A small subset of patients may have life-threatening malformations, which may be more frequent in those with the chromosome 16p13.3 contiguous gene deletion syndrome. 11 Management: Highly dependent on age and phenotype: screening for cardiac and renal defects, immunologic check-up, prevention of infections,detection of diminished vision and hearing loss. Cancer surveillance. Management of behavioral problems. Social support through patient organizations. 
